Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

BACKGROUND: The BCR-ABL1 fusion gene underlying the pathogenesis of CML can arise from a variety of breakpoints. The e13a2 and e14a2 transcripts formed by breakpoints occurring around exon 13 and exon 14 of the BCR gene respectively are the most common. METHODS: We undertook a retrospective audit us...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenfield, Graeme, McMullan, Ross, Robson, Nuala, McGimpsey, Julie, Catherwood, Mark, McMullin, Mary Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498698/
https://www.ncbi.nlm.nih.gov/pubmed/31073408
http://dx.doi.org/10.1186/s12878-019-0139-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498698/
https://www.ncbi.nlm.nih.gov/pubmed/31073408
http://dx.doi.org/10.1186/s12878-019-0139-2

Ejemplares similares